

Paper No. ____
July 8, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WOCKHARDT BIO AG

PETITIONER

V.

ELI LILLY & COMPANY

PATENT OWNER

CASE NO.: UNASSIGNED
PATENT NO. 7,772,209

**PETITION FOR INTER PARTES REVIEW OF
U.S. PATENT NO. 7,772,209 PURSUANT TO
35 U.S.C. §§ 311-319 AND 37 C.F.R. § 42**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	OVERVIEW	2
III.	MANDATORY NOTICES UNDER 37 C.F.R. § 42.8(a)(1).....	4
	A. Real Party-In-Interest	4
	B. Related Matters.....	4
	1. Related Litigations	4
	2. Related Proceedings Before the Board	6
	C. Lead and Back-Up Counsel.....	7
IV.	PAYMENT OF FEES (37 C.F.R. § 42.15(a) and § 42.103).....	8
V.	GROUND FOR STANDING.....	8
VI.	IDENTIFICATION OF CHALLENGE AND STATEMENT OF THE PRECISE RELIEF REQUESTED	8
VII.	THRESHOLD REQUIREMENT FOR <i>INTER PARTES</i> REVIEW	9
VIII.	STATEMENT OF REASONS FOR THE RELIEF REQUESTED	10
	A. Summary of the Argument.....	10
	B. Background of the '209 Patent.....	13
	1. Prior Art Administration of Pemetrexed Resulted in Toxicity Caused by Elevated Homocysteine Levels.....	13
	2. It Was Well-Known that Elevated Baseline Homocysteine Levels Are Most Effectively Treated by Administering Both Folic Acid and Vitamin B ₁₂	15
	3. The '209 Patent	17

4.	The Prosecution of the '209 Patent.....	17
C.	Person of Ordinary Skill in the Art	19
D.	Claim Construction	20
1.	“Patient”	20
2.	The “Effective Amount” Limitations	23
3.	“Methylmalonic Acid Lowering Agent”	24
E.	Patents and Printed Publications Relied on in this Petition	25
1.	Calvert (Ex. 1007) Teaches that Elevated Baseline Homocysteine Levels Associated with Pemetrexed Toxicity Are Caused by Either Folic Acid or Vitamin B ₁₂ Deficiencies.....	25
2.	Niyikiza I (Ex. 1006) Teaches a Strong Correlation between Baseline Homocysteine Levels and Pemetrexed Toxicity.....	26
3.	Worzalla (Ex. 1013) Teaches Pretreating Animal Patients with Folic Acid before Pemetrexed Therapy	27
4.	Hammond I (Ex. 1015) Teaches Pretreating Human Patients with Folic Acid before Starting Pemetrexed Therapy.....	28
F.	The Challenged Claims Are Unpatentable as Obvious over the Prior Art.....	29
1.	Calvert and Niyikiza I Would Have Motivated a POSA to Add Vitamin B ₁₂ to the Folic Acid Pretreatment Regimen of Worzalla or Hammond I	29
a.	A POSA Would Know to Pretreat patients with Vitamin B ₁₂ to Reduce High Homocysteine Levels Linked to Pemetrexed Toxicity.....	29

b.	The Prior Art Taught Combining Antifolates with Vitamin B ₁₂ and Folic Acid	34
2.	Claims 1 and 2 Are Obvious Over Calvert and Niyikiza I in View of Worzalla or Hammond I, and a POSA’s Knowledge of the Relationship between Homocysteine, Folic Acid and Vitamin B ₁₂	36
a.	The POSA Would Have Had a Reasonable Expectation of Success.....	42
b.	No Secondary Considerations Support Non-Obviousness.....	47
c.	The Patent Owner’s “Teaching Away” Arguments Lack Merit.....	51
3.	Claims 3-10, 12, and 14-21 Are Obvious in Further View of the Known Dosages and Schedules for Administering Folic Acid and Vitamin B ₁₂	54
4.	Claim 11 Is Obvious in Further View of the POSA’s Knowledge of the Benefit of Combining Cisplatin with Pemetrexed	60
5.	Claims 13 and 22 Are Obvious over Worzalla or Hammond I in View of Niyikiza I, Calvert in Further View of the POSA’s Knowledge of the Claimed Dosages, Schedules and Combination with Cisplatin	62
IX.	CONCLUSION.....	62

TABLE OF AUTHORITIES

Pages

Cases

<i>Aventis Pharma Deutschland GmbH v. Lupin, Ltd.</i> , 499 F.3d 1293 (Fed. Cir. 2007)	34
<i>Bayer Healthcare Pharm., Inc. v. Watson Pharm. Inc.</i> , 713 F.3d 1369 (Fed. Cir. 2013)	48
<i>Bell Commc 'ns Research, Inc. v. Vitalink Commc 'ns Corp.</i> , 55 F.3d 615 (Fed. Cir. 1995)	34
<i>Bristol-Myers Squibb Co. v. Teva Pharm. USA, Inc.</i> , 923 F. Supp. 2d 602 (D. Del. 2013).....	49
<i>Dow Jones & Co., Inc. v. Ablaise Ltd.</i> , 606 F.3d 1338 (Fed. Cir. 2010)	49
<i>In re Am. Acad. of Sci. Tech Ctr.</i> , 367 F.3d 1359 (Fed. Cir. 2004)	23
<i>In re Cuozzo Speed Techs., LLC</i> , 793 F.3d 1268 (Fed. Cir. 2015)	20
<i>In re Droge</i> , 695 F.3d 1334 (Fed. Cir. 2012)	42
<i>In re Fulton</i> , 391 F.3d 1195 (Fed. Cir. 2004)	51
<i>In re Trans Texas Holdings Corp.</i> , 498 F.3d 1290 (Fed. Cir. 2007)	6
<i>In re Young</i> , 927 F.2d 588 (Fed. Cir. 1991)	53
<i>Key Pharm. Inc. v. Hercon Labs. Corp.</i> , 161 F.3d 709 (Fed. Cir. 1998)	23, 24
<i>Medichem, S.A. v. Rolabo S.L.</i> , 437 F.3d 1157 (Fed. Cir. 2006)	46, 53

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.